Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...

While playing basketball at Boston College, he participated in a point-shaving scheme with Henry Hill, the mobster later ...

Get access to Brad Slager's "Riffed From the Headlines," a daily VIP feature where he looks to bring accountability to the ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Brian Bradley and Rick Peckham remain a part of the Lightning after careers with the team that began in the 1990s. They will ...

In its first conference of 2025, members of the Michigan Supreme Court voted unanimously to retain Elizabeth Clement as the ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Detroit bolstered the backfield in 2023, signing free agent David Montgomery and drafting Jahmyr Gibbs in the first round.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.